Kinase Inhibitors

Publication Date	January 2006
Publisher	BCC Research
Product Type	Report
Pages	153
ISBN Number	not applicable
Product Code	BCC00047

Price

£2,745.00
approximately: $4,847 | €3,481

PDF

PRINT £2,405 ($4,246 | €3,050)

Order above formats by FAX

Summary

Human protein kinases are intriguing drug targets, in part because they regulate a wide variety of signaling pathways and include over 500 distinct protein molecules. Synthetic inhibitors of protein kinases include small molecules that may be easily administered as oral therapeutic compounds. These inhibitors can rapidly and often specifically alter the activation state of a target kinase. They further have significant potential in the clinical treatment of major diseases including cancer, heart disease, inflammatory disorders, diabetes, macular degeneration, and neurological disorders.

This BCC study determines the current status of the kinase inhibitor industry and assesses its growth potential. Only a handful such therapeutics have entered clinical use as of 2005. For each, BCC examined the drug development process, major challenges and achievements and where applicable, the projected market for each of these drugs through 2010.

Of particular interest are up-and-coming kinase inhibitors in clinical trials and preclinical development. Leading candidates are identified in each kinase inhibitor class by molecular target and by disease application. The result is a comprehensive analysis of the current market and its future direction.

Scope Of Study

The report contains:

A thorough review of the technologies employed in the kinase inhibitor
Analysis of the evidence of efficacy and technical limitations of each kinase inhibitor type in clinical use
Analysis of the current market status and growth forecasts through 2010 for each kinase inhibitor
Examination of the potential for additional novel applications
Discussion of the role of government regulations, recent patents and factors affecting the industry worldwide
Analysis of how the development of new kinase inhibitors is translating into new medical therapies for specific disease targets.

Report Highlights

The worldwide market for kinase inhibitors for clinical use will reach $4.63 billion in 2005 and will rise at an average annual growth rate (AAGR) of 20.6% to $11.8 billion by 2010.
Receptor tyrosine kinase inhibitors comprise 49.8% of the total market in 2005 and are projected to grow at an AAGR of 26.6% to account for 63.7% of the total in 2010.
Nonreceptor tyrosine kinase inhibitors, consisting of BCR-Abl kinase inhibitor, reached sales of $1.86 billion in 2005. They are projected to increase at an AAGR of 13.7% to reach $3.56 billion in 2010.
The major disease application for kinase inhibitors is oncology that comprised nearly 90% of kinase inhibitor sales in 2005 and is expected to grow at an AAGR of 21.5%.

Content

Introduction
- Study Goals And Objectives
- Reasons For Doing This Study
- Contributions To The Study And For Whom
- Scope And Format
- Methodology
- Information Sources
- Author's Credentials
- Related BCC Work Credentials
- BCC Online Services
- Disclaimer
Summary
- Summary Table: Global Forecast Of Market For Kinase Inhibitors By Type, Through 2010 ($ Millions)
- Summary Figure: Global Forecast Of Market For Kinase Inhibitors By Type, 2002-2010 ($ Million)
Overview
- The Cellular Role Of Kinases
- Inhibitors Of Protein Kinases
- Kinases As Attractive Drug Targets
- Kinase Inhibitors In Clinical Use And Clinical Trials
- Databases And Large Scale Initiatives
  - Kinbase
  - Kinasenet
  - Kinase Sequence Database (KSD)
  - Kinmutbase
  - Scansite
Technology Overview
- Development Process
- Types Of Kinase Inhibitors
  - Small Molecule Kinase Inhibitors
    - Mechanisms Of Small-Molecule Inhibitors
    - Atp Competitive Inhibitors
    - Non-Atp Competitive Inhibitors
  - Monoclonal Antibodies
- Issues Of Specificity
  - Issues Of Specificity (CONINUED)
- Protein Structure And Modeling
- Rational Design
Patent Evaluation
- Patent Share By Kinase Type
- Recent Patents Of Significance
  - Pharmacia Corp. P38 Inhibitor
  - Cyclacel Cdk Inhibitors
  - Parker Hughes Institute Patent On Egfr Inhibitors And Model
Market For Receptor Tyrosine Kinase Inhibitors
- Total Market Size
- Receptor Tyrosine Kinase Biology
- Inhibitors Of Erbb/Her Family Protein Kinases
- Egfr Inhibitors
  - In Clinical Use
    - Erbitux (CETUXIMAB)
    - Tarceva (ERLOTINIB)
    - Tarceva (ERLOTINIB) (CONTINUD)
    - Iressa (GEFITINIB)
    - Fda Approval In The United States
    - Fast Track Approval In Japan
    - Post-Market Studies Of Iressa
  - Global Market For Egfr Inhibitors
  - In Development
    - Pki-166
    - Canertinib (Ci-1033)
    - Su-11464
    - Matuzumab (Emd7200)
    - Ekb-569
    - Zd6474
- Her2 Inhibitors
  - In Clinical Use
    - Herceptin
  - Her2 Inhibitors In Clinical Development
    - Gw-572016 (Lapatinib Ditosylate)
  - Global Market For Her2 Inhibitors
- Vegf Receptor Tyrosine Kinases
  - Overview
  - Vegf Receptor Kinase Inhibitors In Development
    - Zd6474
    - Pkc-412
    - Sutent (Formerly Su-11248)
    - Vatalanib (Ptk787/Zk222584)
- Flt3 Kinase
  - Overview
  - Flt3 Inhibitors In Clinical Development
    - Cep-701
    - Pkc-412
    - Su5614
    - Sutent (Formerly Su11248)
    - Mln518
    - Xl999
    - Vx-322
Market For Non-Receptor Tyrosine Kinase Inhibitors
- Total Market Size And Background
- Abl Kinases
  - Abl Inhibitors In Clinical Use
    - Gleevec
  - Global Market For Abl Inhibitors
- Src Kinases
  - Overview
  - Src Kinase Inhibitors In Development
    - Azd0530
    - Bms-354825
    - Ski-606
- Targegen Inhibitor
- Janus (JAK) Kinases
  - Overview
  - Jak Inhibitors In Development
    - Cp-690
    - Ag-490
    - Whi-P154, Whi-P131
Market For Serine-Threonine Kinase Inhibitors
- Total Market Size
- Mtor Kinases
  - Overview
  - Mtor Inhibitors In Clinical Use
    - Rapamune
    - Certican (EVEROLIMUS)
  - Global Market For Mtor Inhibitors
  - Mtor Inhibitors In Development
    - Ap23573
- Rho Kinases
  - Overview
  - Rho Kinase Family Inhibitors In Clinical Use
    - Eril (Fasudil Hydrochloride)
  - Global Market For Rho Kinase Inhibitors
- Cyclin Dependent Kinases
  - Overview
  - Cdk Inhibitors In Clinical Development
    - Flavopiridol
    - Seliciclib (Cyc202, Roscovitine)
    - Sns-032 (Formerly Bms-387032)
- Protein Kinase C (PKC)
  - Overview
  - Pkc Inhibitors In Clinical Development
    - Ruboxistaurin
    - Pkc412
    - Bryostatin
    - Kai-9803
- Phosphatidylinositol-3-Kinase (Pi3k)
  - Overview
  - Pi3 Kinase Inhibitors In Clinical Development
    - Sf1126
- Aurora Kinases
  - Overview
  - Aurora Kinase Inhibitors In Clinical Development
    - Vx-680
    - Azd1152
- Map/Mek Kinases
  - Overview
  - Mapk/Mek Inhibitors In Clinical Development
    - Arry-142886 (Azd-6244)
    - Scio-469
    - Gw681323 (Sb-681323)
- Jun N-Terminal Kinases (JNK)
  - Overview
  - Jnk Inhibitors In Clinical Development
    - Cc-401
    - Cep-1347
Market For Kinase Inhibitors By Disease Application
- Total Market Size
- Current Applications
  - Cancer
    - Market Size By Kinase Inhibitors
    - Types Of Cancer
    - Lung Cancer
    - Egfr Inhibitors For Lung Cancer Treatment
    - Breast Cancer
    - Erb/Her2 Inhibitors For Breast Cancer Treatment
    - Cdk Inhibitors For Breast Cancer Treatment
    - Leukemias
    - Chronic Myeloid Leukemia (CML)
    - Acute Myeloid Leukemia (AML)
    - Bcr-Abl Inhibitors For Leukemia Treatment
    - Flt3 Inhibitors For Leukemia Treatment
    - Colorectal Cancer
    - Egfr Inhibitors For Colorectal Cancer
    - Pancreatic Cancer
    - Egfr Inhibitors For Pancreatic Cancer Treatment
    - Skin Cancers
    - Basal Cell Carcinoma
    - Squamous Cell Carcinoma
    - Melanoma
    - Egfr Inhibitors For Skin Cancer Treatment
    - Mapk/Erk Inhibitors For Skin Cancer Treatment
    - Pkc Inhibitors For Skin Cancer Treatment
    - Pi3k Inhibitors For Skin Cancer Treatment
    - Ras/Raf Inhibitors In Skin Cancer Treatment
  - Immune And Inflammatory Diseases
    - Market Size By Kinase Inhibitors
    - Immunosuppression For Organ Transplantation
    - Mtor Inhibitors For Immunosuppression
    - Asthma
    - Mapk Inhibitors In Asthma Treatment
    - Arthritis
    - Mapk Inhibitors In Arthritis Treatment
  - Cardiovascular Disease
    - Market Size By Kinase Inhibitors
    - Rho Kinases For Cardiovascular Disease
    - Mapk Inhibitors For Cardiovascular Treatment
    - Mek/Mapk1 Inhibitors For Cardiovascular Disease
    - Jnk Inhibitors For Cardiovascular Disease
- Emerging Applications
  - Diabetes
    - Vegf Inhibitors For Treatment Of Diabetes
    - Flt3 Inhibitors For Treatment Of Diabetes
    - Pkc Inhibitors In The Treatment Of Diabetes
  - Macular Degeneration
    - Vegf Inhibitors For Macular Degeneration
  - Neurological Disease
    - Gsk Kinase Inhibitors For Neurological Disease
    - Cdk Inhibitors For Neurological Disease
Major Companies And Market Share
- Market Shares
Company Profiles
- Ambit Biosciences
- Amgen
- Ariad Pharmaceuticals
- Astrazeneca
- Boehringer Ingelheim
- Cephalon Inc.
- Ceptyr, Inc.
- Cgi Pharmaceuticals, Inc
- Chiron, Inc.
- Cyclacel Limited
- Exelixis
- Genentech Inc.
- Glaxosmithkline
- Gpc Biotech Ag
- Imclone Systems
- Kai Pharmaceuticals
  - Kémia
- Kinexus Bioinformatics Corp.
- Merck And Co.
- Millenium Pharmaceuticals
- Myriad Genetics, Inc.
- Novartis
- Pfizer Inc.
- Roche (F. Hoffmann-La Roche Ltd)
  - Sanofi-Aventis
- Scios
  - Targegen
- Vertex
- Wyeth-Ayerst
International Aspects And Regulatory Issues
- Market By Region
- United States
  - Drug Withdrawals
    - Vioxx
    - Iressa
  - Consumer Confidence
  - Medicare
- European Union
  - New Drug Approvals And Innovation
  - Costs Of Drug Development
  - Relocation Of R&d
  - Regulatory Climate
- Japan
  - New Drug Approvals
  - Regulatory Climate
  - Relationship Of Academia And Industry
  - Venture Capital
Future Directions
- Specificity And Complexity
- Resistance
- Kinase Activators
- Developments In Enabling Technologies
  - Phosphorylation-State Antibodies
  - High Throughput Kinase Assays
List Of Figures
- Summary Table: Global Forecast Of Market For Kinase Inhibitors By Type, Through 2010 ($ Millions)
- Table 1 Attractive Features Of Protein Kinases
- Table 2 Fda-Approved* Kinase Inhibitors
- Table 3 Kinase Inhibitors In Clinical Trials
- Table 4 Number Of Kinase Inhibitors In Clinical Trials, By Phase
- Table 5 Companies With Kinase Inhibitors In Clinical Trials
- Table 6 Kinase Databases
- Table 7 Comparison Of Types Of Inhibitors
- Table 8 Comparison Of Atp Competitive And Noncompetitive Inhibitors
- Table 9 Kinase Inhibitor Patents By Target Molecule, August 2003 To August 2005
- Table 10 Kinase Inhibitor Patents By Disease, August 2003 To August 2005
- Table 11 Kinase Inhibitor Patents By Assignee
- Table 12 Kinase Inhibitor Patents By Region, 2004
- Table 13 Global Forecast For Receptor Tyrosine Kinase Inhibitors Market By Product, Through 2010 ($ Millions)
- Table 14 Global Market For Egfr Inhibitors By Region, Through 2010 ($ Millions)
- Table 15 Global Market For Her2 Inhibitors By Region, Through 2010 ($ Millions)
- Table 16 Global Forecast For Nonreceptor Tyrosine Kinase Inhibitors Market By Product, Through 2010 ($ Millions)
- Table 17 Global Forecast For Abl Inhibitors Market By Region, Through 2010 ($ Millions)
- Table 18 Global Forecast For Serine-Threonine Kinase Inhibitors Market By Product, Through 2010 ($ Millions)
- Table 19 Global Market For Mtor Inhibitors By Region, Through 2010 ($ Millions)
- Table 20 Global Market For Rho Kinase Inhibitors By Region, Through 2010 ($ Millions)
- Table 21 Global Forecast For Kinase Inhibitors Market By Current Applications, Through 2010 (Unit?)
- Table 22 Global Forecast For Kinase Inhibitors Market In Cancer Treatment By Product, Through 2010 ($ Millions)
- Table 23 Worldwide Market For Kinase Inhibitors In Immune And Inflammatory Disease By Product, Through 2010 (Units Millions)
- Table 24 Global Forecast For Kinase Inhibitors Market In Cardiovascular Disease Treatment By Product, Through 2010 ($ Million)
- Table 25 Sales And Market Share Of Companies Involved In Kinase Inhibitors, 2005 ($ Millions And %)
- Table 26 Sales And Market Share Of Companies Involved In Tyrosine Kinase Inhibitors, 2005 ($ Millions And %)
- Table 27 Sales And Market Share Of Companies Involved In Serine Threonine Kinase Inhibitors, 2005 ($ Millions And %)
- Table 28 Global Forecast For Kinase Inhibitors Market By Region, Through 2010 ($ Millions)
List Of Figures
- Summary Figure: Global Forecast Of Market For Kinase Inhibitors By Type, 2002-2010 ($ Million)
- Figure 1 Global Forecast For Receptor Tyrosine Kinase Inhibitors Market By Product, 2002-2010 ($ Millions)
- Figure 2 Global Forecast For Nonreceptor Tyrosine Kinase Inhibitors Market, 2002-2010 ($ Millions)
- Figure 3 Global Forecast For Serine-Threonine Kinase Inhibitors Market By Product, 2002-2010 ($ Millions)
- Figure 4 Regional Share Of Global Market For Kinase Inhibitors, 2005 And 2010 (%)